Skip to content

Study · In vitro (cells) · 1999

4 results

Interactions between growth hormone, insulin-like growth factor I, and basic fibroblast growth factor in melanocyte growth.

Edmondson SR, Russo VC, McFarlane AC, Wraight CJ, Werther GA

The Journal of clinical endocrinology and metabolism1 May 1999Cited by 38 (Europe PMC)

PMID10323393 (opens in a new tab)DOI10.1210/jcem.84.5.5692 (opens in a new tab)PepBankPUB-10323393
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    Des(1‑3)IGF-I enhanced cultured melanocyte growth in a dose-dependent manner.

    In plain wordsIn cells, des(1‑3)IGF-I increased pigment cell growth as dose increased.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMelanocyte growth
    Study

    humann: not reported in source

    cultured human melanocytes
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    in contrast to the lack of effect of GH or bFGF alone, both IGF-I and des(1-3)IGF-I enhance melanocyte growth in a dose-dependent manner
  2. 02LabIn vitro (cells)Activity measurement

    Des(1‑3)IGF-I was less efficacious than IGF-I at eliciting melanocyte growth at low concentrations.

    In plain wordsIn cells, des(1‑3)IGF-I produced less pigment cell growth than IGF-I at low concentrations.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseGrowth efficacy at low concentrations
    Study

    humann: not reported in source

    cultured human melanocytes
    Comparator
    IGF-I
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-I is more efficacious in eliciting a growth response at low concentrations compared to des(1-3)IGF-I.

Studies that did not test the peptide alone2

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 03LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Activity measurement

    GH combined with des(1‑3)IGF-I stimulated cultured melanocyte growth.

    In plain wordsIn cells, GH combined with des(1‑3)IGF-I increased pigment cell growth.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseGrowth with GH combination
    Study

    humann: not reported in source

    cultured human melanocytes
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    GH stimulates the growth of melanocytes when combined with IGF-I, des(1-3)IGF-I [an analog of IGF-I that has a reduced binding affinity for IGF-binding proteins (IGFBPs)], or bFGF, either separately or in combination

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  2. 04LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    IGFBP-4 was the major binding protein produced by melanocytes cultured with des(1‑3)IGF-I alone.

    In plain wordsIn cells, IGFBP-4 was the main binding protein produced during exposure to des(1‑3)IGF-I alone.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Not applicableMajor secreted IGF-binding protein
    Study

    humann: not reported in source

    cultured human melanocytes
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    IGFBP-4 is the major IGFBP produced by these cells when cultured in complete growth medium or in the presence of either IGF-I or des(1-3)IGF-I alone.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.